SLC2A9: Glucose Transporter and Potential Drug Target (G56606)

Target Name: SLC2A9

NCBI ID: G56606

SLC2A9

SLC2A9: Glucose Transporter and Potential Drug Target

SLC2A9 (SLC2A9 (GLUT9)) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and pancreas. It is a member of the selective transport system family 2 (SLC2) and is responsible for transporting a variety of molecules, including glucose, across cell membranes. SLC2A9 is also known as GLUT9, which stands for glucose-transporter 9.

SLC2A9 is a protein that is expressed in the brain, where it is involved in the transportation of glucose to the mitochondria, where it can be used for energy production. It is also expressed in the heart, where it is involved in the transportation of oxygen -carrying red blood cells to the lungs to be oxygenated. In the liver, SLC2A9 is involved in the transportation of glucose to the liver cells for energy production. In the pancreas, SLC2A9 is involved in the transportation of insulin across the cell membrane to the pancreatic beta cells, where it is used to regulate blood sugar levels.

SLC2A9 is a protein that is known for its role in the development and progression of various diseases, including diabetes. It is thought to play a role in the regulation of insulin sensitivity, as well as the regulation of blood sugar levels. SLC2A9 has also been shown to be involved in the development of certain types of cancer, including breast and ovarian cancer.

SLC2A9 is also a potential drug target, as it is thought to be involved in the regulation of a variety of cellular processes, including metabolism, cell signaling, and cancer. It is also thought to be involved in the regulation of the immune system, as it has been shown to be involved in the production of certain immune cells.

SLC2A9 is also a potential biomarker, as it can be used to diagnose and monitor a variety of diseases, including diabetes, cancer, and immune system disorders. It is also thought to be involved in the regulation of insulin sensitivity, which could make it an attractive target for interventions aimed at improving insulin sensitivity in people with diabetes.

In conclusion, SLC2A9 is a protein that is expressed in various tissues throughout the body and is involved in the transportation of glucose across cell membranes. It is also known as GLUT9 and is thought to play a role in the regulation of insulin sensitivity, as well as the regulation of blood sugar levels. SLC2A9 is a potential drug target and biomarker, and further research is needed to fully understand its role in the regulation of cellular processes and diseases.

Protein Name: Solute Carrier Family 2 Member 9

Functions: High-capacity urate transporter, which may play a role in the urate reabsorption by proximal tubules (PubMed:18327257, PubMed:28083649, PubMed:22647630, PubMed:18701466). May have a residual high-affinity, low-capacity glucose and fructose transporter activity (PubMed:18842065, PubMed:18327257, PubMed:18701466). Transports urate at rates 45- to 60-fold faster than glucose (PubMed:18842065). Does not transport galactose (PubMed:28083649). May mediate small uptake of adenine but not of other nucleobases (PubMed:22647630)

The "SLC2A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets